Analysis of MDR1 expression in normal and malignant endometrium by reverse transcription-polymerase chain reaction and immunohistochemistry

Dennis Yi-Shin Kuo, Shyamali Mallick, Heng Jia Shen, Carol DeVictoria, Joan Jones, Abbie L. Fields, Gary L. Goldberg, Carolyn D. Runowicz, Susan Band Horwitz

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The purpose of this study was to quantitate the expression of human MDR1 mRNA levels in normal endometrium and in endometrial carcinoma and to determine the association of MDR1 levels with prognostic indicators. Endometrial samples from 43 postmenopausal patients with endometrial carcinoma and 38 patients (controls) with benign disease undergoing hysterectomy were snap-frozen. MDR1 levels were determined by quantitative reverse transcription-PCR (RT-PCR) and compared to sensitive and resistant cell lines. Immunohistochemistry was done with MM4.17, an anti-MDR1 antibody, on paraffin sections, and the results were compared to those obtained from RT-PCR. Data was analyzed using the Kruskal-Wallis and Bonferroni tests, setting the P value at 0.05. In both postmenopausal endometrial tissue and tumors, MDR1 expression was localized to the epithelial cell layer. Comparison of immunohistochemistry and RT-PCR results demonstrated a correlation of 80%. In control patients, MDR1 expression was significantly higher in postmenopausal endometrium (n = 15) than in the proliferative premenopausal endometrium (n = 15; P = 0.0024). MDR1 expression in all tumors was lower than that measured in the postmenopausal controls. Between each tumor group, there was no significant difference in the MDR1 levels observed. MDR1 expression was significantly lower in patients with high nuclear grade (n = 18) tumors when compared to patients with low nuclear grade (n = 14; P = 0.04) tumors. Comparison of MDR1 levels with multiple prognostic indicators for endometrial cancer was only significant for nuclear grade. The data indicate that MDR1 expression is not a major component of the drug resistance observed in primary endometrial tumors.

Original languageEnglish (US)
Pages (from-to)1981-1992
Number of pages12
JournalClinical Cancer Research
Volume2
Issue number12
StatePublished - Dec 1996

Fingerprint

Endometrium
Reverse Transcription
Immunohistochemistry
Polymerase Chain Reaction
Endometrial Neoplasms
Neoplasms
Hysterectomy
Drug Resistance
Paraffin
Anti-Idiotypic Antibodies
Epithelial Cells
Cell Line
Messenger RNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Analysis of MDR1 expression in normal and malignant endometrium by reverse transcription-polymerase chain reaction and immunohistochemistry. / Kuo, Dennis Yi-Shin; Mallick, Shyamali; Shen, Heng Jia; DeVictoria, Carol; Jones, Joan; Fields, Abbie L.; Goldberg, Gary L.; Runowicz, Carolyn D.; Band Horwitz, Susan.

In: Clinical Cancer Research, Vol. 2, No. 12, 12.1996, p. 1981-1992.

Research output: Contribution to journalArticle

Kuo, DY-S, Mallick, S, Shen, HJ, DeVictoria, C, Jones, J, Fields, AL, Goldberg, GL, Runowicz, CD & Band Horwitz, S 1996, 'Analysis of MDR1 expression in normal and malignant endometrium by reverse transcription-polymerase chain reaction and immunohistochemistry', Clinical Cancer Research, vol. 2, no. 12, pp. 1981-1992.
Kuo, Dennis Yi-Shin ; Mallick, Shyamali ; Shen, Heng Jia ; DeVictoria, Carol ; Jones, Joan ; Fields, Abbie L. ; Goldberg, Gary L. ; Runowicz, Carolyn D. ; Band Horwitz, Susan. / Analysis of MDR1 expression in normal and malignant endometrium by reverse transcription-polymerase chain reaction and immunohistochemistry. In: Clinical Cancer Research. 1996 ; Vol. 2, No. 12. pp. 1981-1992.
@article{2301cb4ad3404651ade029a16e457480,
title = "Analysis of MDR1 expression in normal and malignant endometrium by reverse transcription-polymerase chain reaction and immunohistochemistry",
abstract = "The purpose of this study was to quantitate the expression of human MDR1 mRNA levels in normal endometrium and in endometrial carcinoma and to determine the association of MDR1 levels with prognostic indicators. Endometrial samples from 43 postmenopausal patients with endometrial carcinoma and 38 patients (controls) with benign disease undergoing hysterectomy were snap-frozen. MDR1 levels were determined by quantitative reverse transcription-PCR (RT-PCR) and compared to sensitive and resistant cell lines. Immunohistochemistry was done with MM4.17, an anti-MDR1 antibody, on paraffin sections, and the results were compared to those obtained from RT-PCR. Data was analyzed using the Kruskal-Wallis and Bonferroni tests, setting the P value at 0.05. In both postmenopausal endometrial tissue and tumors, MDR1 expression was localized to the epithelial cell layer. Comparison of immunohistochemistry and RT-PCR results demonstrated a correlation of 80{\%}. In control patients, MDR1 expression was significantly higher in postmenopausal endometrium (n = 15) than in the proliferative premenopausal endometrium (n = 15; P = 0.0024). MDR1 expression in all tumors was lower than that measured in the postmenopausal controls. Between each tumor group, there was no significant difference in the MDR1 levels observed. MDR1 expression was significantly lower in patients with high nuclear grade (n = 18) tumors when compared to patients with low nuclear grade (n = 14; P = 0.04) tumors. Comparison of MDR1 levels with multiple prognostic indicators for endometrial cancer was only significant for nuclear grade. The data indicate that MDR1 expression is not a major component of the drug resistance observed in primary endometrial tumors.",
author = "Kuo, {Dennis Yi-Shin} and Shyamali Mallick and Shen, {Heng Jia} and Carol DeVictoria and Joan Jones and Fields, {Abbie L.} and Goldberg, {Gary L.} and Runowicz, {Carolyn D.} and {Band Horwitz}, Susan",
year = "1996",
month = "12",
language = "English (US)",
volume = "2",
pages = "1981--1992",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Analysis of MDR1 expression in normal and malignant endometrium by reverse transcription-polymerase chain reaction and immunohistochemistry

AU - Kuo, Dennis Yi-Shin

AU - Mallick, Shyamali

AU - Shen, Heng Jia

AU - DeVictoria, Carol

AU - Jones, Joan

AU - Fields, Abbie L.

AU - Goldberg, Gary L.

AU - Runowicz, Carolyn D.

AU - Band Horwitz, Susan

PY - 1996/12

Y1 - 1996/12

N2 - The purpose of this study was to quantitate the expression of human MDR1 mRNA levels in normal endometrium and in endometrial carcinoma and to determine the association of MDR1 levels with prognostic indicators. Endometrial samples from 43 postmenopausal patients with endometrial carcinoma and 38 patients (controls) with benign disease undergoing hysterectomy were snap-frozen. MDR1 levels were determined by quantitative reverse transcription-PCR (RT-PCR) and compared to sensitive and resistant cell lines. Immunohistochemistry was done with MM4.17, an anti-MDR1 antibody, on paraffin sections, and the results were compared to those obtained from RT-PCR. Data was analyzed using the Kruskal-Wallis and Bonferroni tests, setting the P value at 0.05. In both postmenopausal endometrial tissue and tumors, MDR1 expression was localized to the epithelial cell layer. Comparison of immunohistochemistry and RT-PCR results demonstrated a correlation of 80%. In control patients, MDR1 expression was significantly higher in postmenopausal endometrium (n = 15) than in the proliferative premenopausal endometrium (n = 15; P = 0.0024). MDR1 expression in all tumors was lower than that measured in the postmenopausal controls. Between each tumor group, there was no significant difference in the MDR1 levels observed. MDR1 expression was significantly lower in patients with high nuclear grade (n = 18) tumors when compared to patients with low nuclear grade (n = 14; P = 0.04) tumors. Comparison of MDR1 levels with multiple prognostic indicators for endometrial cancer was only significant for nuclear grade. The data indicate that MDR1 expression is not a major component of the drug resistance observed in primary endometrial tumors.

AB - The purpose of this study was to quantitate the expression of human MDR1 mRNA levels in normal endometrium and in endometrial carcinoma and to determine the association of MDR1 levels with prognostic indicators. Endometrial samples from 43 postmenopausal patients with endometrial carcinoma and 38 patients (controls) with benign disease undergoing hysterectomy were snap-frozen. MDR1 levels were determined by quantitative reverse transcription-PCR (RT-PCR) and compared to sensitive and resistant cell lines. Immunohistochemistry was done with MM4.17, an anti-MDR1 antibody, on paraffin sections, and the results were compared to those obtained from RT-PCR. Data was analyzed using the Kruskal-Wallis and Bonferroni tests, setting the P value at 0.05. In both postmenopausal endometrial tissue and tumors, MDR1 expression was localized to the epithelial cell layer. Comparison of immunohistochemistry and RT-PCR results demonstrated a correlation of 80%. In control patients, MDR1 expression was significantly higher in postmenopausal endometrium (n = 15) than in the proliferative premenopausal endometrium (n = 15; P = 0.0024). MDR1 expression in all tumors was lower than that measured in the postmenopausal controls. Between each tumor group, there was no significant difference in the MDR1 levels observed. MDR1 expression was significantly lower in patients with high nuclear grade (n = 18) tumors when compared to patients with low nuclear grade (n = 14; P = 0.04) tumors. Comparison of MDR1 levels with multiple prognostic indicators for endometrial cancer was only significant for nuclear grade. The data indicate that MDR1 expression is not a major component of the drug resistance observed in primary endometrial tumors.

UR - http://www.scopus.com/inward/record.url?scp=0030474493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030474493&partnerID=8YFLogxK

M3 - Article

C2 - 9816157

AN - SCOPUS:0030474493

VL - 2

SP - 1981

EP - 1992

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 12

ER -